An interventional study of Syde and Dynamometric measurements of muscle strength in Neuromuscular Diseases, Obesity (Disorder) and Myotonic Dystrophy 1, sponsored by Centre Hospitalier Universitaire de Liege. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Centre Hospitalier Universitaire de Liege · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Neuromuscular Diseases with a site in Belgium — 7 open to participants now, 11 under way, 3 of them phase 3. Neuromuscular Diseases · Belgium.
Among the 23 studies in Neuromuscular Diseases with a site in Belgium, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 21st registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →7 of the 23 studies in Neuromuscular Diseases with a site in Belgium are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Belgium, Australia, Canada and 7 more countries
Ages 7–16 · Men only
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 6–12 · Healthy volunteers
Université Catholique de Louvain · Sites in Belgium
Ages 12–50
Laurent Servais · Sites in Belgium
Ages 2+ · Healthy volunteers
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages up to 18
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 8
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 30 across 204 interventional studies indexed under Neuromuscular Diseases.
Median enrollment 77 across the 20 interventional studies, 300 across the 3 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 23 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Liege is the lead sponsor of 40 studies on the registry; 26 are open to participants now.
Centre Hospitalier Universitaire de Liege has 1 study filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Neuromuscular Diseases with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Neuromuscular Diseases with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.
Following the qualification of the 95th centile of stride velocity (SV95C) as a primary digital endpoint in Duchenne muscular dystrophy (DMD), there is growing interest in extending such digital assessments to other neurological and metabolic diseases that impair movement. Traditional in-clinic functional tests (e.g., 6-minute walk test, 10-meter walk/run) provide only limited snapshots of motor ability and are influenced by external factors such as motivation and fatigue. Similarly, motor function scales and biomarkers, while useful, often lack objectivity or established clinical relevance.
The ActiLiège-Adult study aims to address these limitations by leveraging the Syde® device, a wearable magneto-inertial sensor worn on the wrist and/or ankle, to continuously monitor motor activity in daily life. This device has been previously validated in DMD and other neuromuscular conditions and has been used in both interventional and natural history studies.
This academic study will enroll 300 ambulant adult patients, including 220 with neurological diseases and 20 with obesity, with a minimum of 20 patients per disease type. Ambulation is defined as the ability to walk 10 meters unaided. Patients who lose ambulation during the study will continue to be followed with adapted assessments.
Participants will be monitored for up to two years (six months for diseases affecting the neuromuscular junction). Standardized clinical assessments-including timed tests, motor function evaluations, and strength measurements-will be conducted at baseline and every six months. These will be compared with continuous data collected by the Syde® device. Additionally, patients will complete a Patient Global Impression of Change (PGI-C) questionnaire every six months.
The study's goal is to generate robust, real-world data to support the development of objective, sensitive, and clinically meaningful digital endpoints for use in future therapeutic trials targeting movement disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis by the investigator based on current gold standard in his/her disease (genetic testing, clinical criteria, etc.)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Syde · Diagnostic Test: The 6-minute walk test (6MWT) · Diagnostic Test: The 10-meter test (10MWT) · Diagnostic Test: The 4 stair-climbing test (4SC) · Diagnostic Test: Test of rising from the floor (TRF) · Other: Patient's Global Impression of Change (PGIC)
Device: Syde · Diagnostic Test: Dynamometric measurements of muscle strength · Diagnostic Test: The 6-minute walk test (6MWT) · Diagnostic Test: The 10-meter test (10MWT) · Diagnostic Test: The 4 stair-climbing test (4SC) · Diagnostic Test: Test of rising from the floor (TRF) · Diagnostic Test: The Charcot-Marie-Tooth examination score (CMTES) · Diagnostic Test: 9-Hole Peg Test (9-HPT) · Other: Patient's Global Impression of Change (PGIC)
Device: Syde · Diagnostic Test: The 6-minute walk test (6MWT) · Diagnostic Test: The 10-meter test (10MWT) · Diagnostic Test: The 4 stair-climbing test (4SC) · Diagnostic Test: Test of rising from the floor (TRF) · Diagnostic Test: 9-Hole Peg Test (9-HPT) · Diagnostic Test: The Scale for the Assessment and Rating of Ataxia (SARA) · Other: Patient's Global Impression of Change (PGIC)
Device: Syde · Diagnostic Test: The 6-minute walk test (6MWT) · Diagnostic Test: The 10-meter test (10MWT) · Diagnostic Test: The 4 stair-climbing test (4SC) · Diagnostic Test: Test of rising from the floor (TRF) · Diagnostic Test: The Unified Huntington's Disease Rating Scale (UHDRS) · Other: Patient's Global Impression of Change (PGIC)
Device: Syde · Diagnostic Test: The 6-minute walk test (6MWT) · Diagnostic Test: The 10-meter test (10MWT) · Diagnostic Test: The 4 stair-climbing test (4SC) · Diagnostic Test: Test of rising from the floor (TRF) · Diagnostic Test: The Timed up and go test (TUG) · Diagnostic Test: The Progressive Supranuclear Palsy Rating Scale (PSP-RS) · Diagnostic Test: The Montreal Cognitive Assessment (MOCA) · Other: Patient's Global Impression of Change (PGIC)
Device: Syde · Diagnostic Test: The 6-minute walk test (6MWT) · Diagnostic Test: The 10-meter test (10MWT) · Diagnostic Test: The 4 stair-climbing test (4SC) · Diagnostic Test: Test of rising from the floor (TRF) · Other: Patient's Global Impression of Change (PGIC)
Device: Syde · Diagnostic Test: The 6-minute walk test (6MWT) · Diagnostic Test: The 10-meter test (10MWT) · Diagnostic Test: The 4 stair-climbing test (4SC) · Diagnostic Test: Test of rising from the floor (TRF) · Other: Patient's Global Impression of Change (PGIC)
Device: Syde · Diagnostic Test: The 6-minute walk test (6MWT) · Diagnostic Test: The 10-meter test (10MWT) · Diagnostic Test: The 4 stair-climbing test (4SC) · Diagnostic Test: Test of rising from the floor (TRF) · Diagnostic Test: Quantitative Myasthenia Gravis (QMG) · Diagnostic Test: The Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) · Other: Patient's Global Impression of Change (PGIC)
Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Dynamometric measurements of the maximum force of the following functions will be taken with the MyoTools: palmar grip (MyoGrip) and thumb-index pinch (MyoPinch). Test will be realized on the dominant side. Patients will be encouraged during the test. They will be given three trials and the best score will be entered.
This test consists of covering the greatest possible distance within 6 minutes, walking back and forth along a 25-meter hallway. The subject may stop if they need to. The evaluator will record the elapsed time after each half-lap, and the final distance that was covered at the end of the test. No help will be allowed during the test.
During this test, the subject must cover a distance of 10 meters as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test. No help will be allowed during the test.
This is a standardized test during which the subject must climb the 4 stair steps as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test, or more if needed.
This is a standardized test during which the subject must rise from the floor as rapidly as possible. The test starts with the participant lying on their back. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test.
During this standardized test, the subject is observed and timed while he/she rises from a chair, walks 3 meters, performs a 180° turn, walk back toward the chair and sits down.
This 28-item clinician-rated scale assesses motor and non-motor symptom severity in patients with PSP, with a score ranging from 0 (normal) to 100.
The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0 to 30, with higher score being better outcome.
The CMTES is a 28-point composite score that rates the patient's symptoms and signs. It is part of the Charcot-Marie-Tooth (CMT) neuropathy score and has been validated as a reproducible measure of disability in CMT. Higher scores indicate more severe neuropathy.
The 9-HPT is a quantitative test of upper limb function. It is the second component of the Multiple Sclerosis Functional Composite (MSFC). The patient sits at a table with a shallow container containing nine sticks and a wooden or plastic block containing nine empty holes. When a timer is started, the patient places the nine sticks one after the other as quickly as possible into the nine holes and, once they are all in the holes, removes them as quickly as possible. The total time taken to complete the task is recorded. Two consecutive attempts with the dominant hand are immediately followed by two consecutive attempts with the non-dominant hand.
This 74-item clinical rating scale assesses patient performance and capacity in 4 domains: motor function, cognitive function, behavioral abnormalities, and functional capacity.
The QMG is a clinician-rated 13-item scale used to quantify disease severity in patients with MG. The scale grades each domain (ocular, bulbar, respiratory, and limb function), with a total score ranging from 0 to 39 (lower score indicating a better clinical outcome).
This is an 8-item patient-reported scale assessing MG symptoms and their effects on daily activities. The score ranges from 0 to 24, with higher score indicating a worse clinical outcome.
This 8-item scale was developed to assess ataxia severity and disease progression. It evaluates gait and balance, speech, and upper and lower limb coordination. The score ranges from 0 to 40, with higher score indicating a worse clinical outcome.
PGIC is a patient-reported scale used to assess how a patient feels their condition has changed over time. It typically uses a 7-point scale to capture the patient's overall perception of improvement in symptoms, function, and quality of life.
95th Centile of Stride Velocity (SV95C)
Change in SV95C as measured by the Syde® wearable device, used to assess ambulatory function in real-life settings.
Time frame: Every 6 months for up to 2 years
Device Acceptability and Adherence
Measures of user engagement with the Syde® device over time, including total recording time, valid days (≥5 hours), and time to reach 50 and 180 hours.
Time frame: Over 2 years
Correlation between Syde® and 6MWT
Correlation between the Syde digital variable and results from the 6-minute walk test (6MWT)
Time frame: Every 6 months for up to 2 years
Correlation between Syde® and 10MWT
Correlation between the Syde digital variable and results from the 10-meter test (10MWT)
Time frame: Every 6 months for up to 2 years
Correlation between Syde® and 4SC
Correlation between the Syde digital variable and results from the 4 stair-climbing test (4SC)
Time frame: Every 6 months for up to 2 years
Correlation between Syde® and TRF
Correlation between the Syde digital variable and results from the test of rising from the floor (TRF)
Time frame: Every 6 months for up to 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2029, 69 months after the start.
Of 75 non-industry interventional studies with no phase under Neuromuscular Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 47. This study's planned 69 months is above that.
Counting every sponsor, half of 84 studies reached it within 25 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Liege